Masseter hypertrophy
Masseter hypertrophy is enlargement of the masseter, a major chewing muscle at the angle of the jaw. Botulinum toxin type A can reduce masseter activity and muscle volume, but “masseter Botox” is an imprecise umbrella term: visible muscle enlargement, elective lower-face contouring, bruxism, jaw pain, and temporomandibular disorders (TMD) involve different diagnoses, goals, and evidence. A 2026 meta-analysis supports short-term improvements in muscle prominence and thickness compared with placebo, while finding substantial variation between trials. (Masseter hypertrophy meta-analysis — JPRAS 🔗)
Approval is specific to the product, indication, and country. Chinese reporting describes an additional Hengli indication for benign masseter hypertrophy; the U.S. Botox Cosmetic application concerns a proposed use under review. Neither establishes approval for bruxism or jaw pain.
Four Questions Commonly Collapsed Into One
Section titled “Four Questions Commonly Collapsed Into One”| Use context | Main question | What should not be inferred |
|---|---|---|
| Benign masseter hypertrophy | Is the masseter itself enlarged, and is the concern functional, aesthetic, or both? | A broad lower face or jaw symptom does not by itself establish muscle hypertrophy. |
| Lower-face contouring | Can reducing masseter volume change bigonial width or lower-face shape? | A contouring outcome does not establish benefit for pain, bruxism, or joint disease. |
| Bruxism | Does the person have sleep or awake bruxism, and which outcome is being measured? | Reduced muscle activity or bite force does not necessarily eliminate the behavior or its cause. |
| Temporomandibular disorder or jaw pain | Is the problem muscular, articular, dental, neurologic, or mixed? | Evidence about masseter size cannot be transferred directly to a heterogeneous pain disorder. |
Masseter prominence can also reflect skeletal shape, soft tissue, parotid-region anatomy, asymmetry, or another condition. Masseter hypertrophy is therefore a use context, not a diagnosis that can be made from facial shape alone.
Regulatory and Product Context
Section titled “Regulatory and Product Context”| Country and product | Named use | Regulatory milestone and evidence | Interpretation limit |
|---|---|---|---|
| China — Hengli | Temporary improvement of benign masseter hypertrophy | People’s Health reports NMPA approval of an additional indication on April 27, 2026. (People’s Health report 🔗) | Reporting does not provide the full revised label or detailed patient criteria. |
| United States — Botox Cosmetic | Proposed temporary improvement of marked to very marked masseter muscle prominence associated with muscle activity in adults | Allergan Aesthetics announced FDA acceptance of a supplemental Biologics License Application on August 4, 2026. (Allergan Aesthetics announcement 🔗) | Acceptance for review does not add the proposed indication to the label. |
The BOTOX 🔗 and BOTOX Cosmetic 🔗 U.S. indication lists do not include masseter hypertrophy, bruxism, jaw tension, or TMD. This is an inference from those product labels, rather than a claim about every product or jurisdiction. The U.S. regulatory-status record separates the proposed masseter indication from approved uses.
The Chinese and U.S. wording differs, and neither should be broadened to general facial slimming, bruxism, or joint disease. A shared type A classification does not establish a shared indication, formulation, dose, or unit scale.
What the Evidence Supports—and Does Not Settle
Section titled “What the Evidence Supports—and Does Not Settle”A 2013 Cochrane review found no eligible randomized controlled trials for benign bilateral masseter hypertrophy. That conclusion describes its historical evidence search, rather than the evidence available today. (Botulinum toxin for masseter hypertrophy — Cochrane 🔗)
A 2026 systematic review and meta-analysis included five placebo-controlled randomized trials involving 536 participants. It found short-term improvement in masseter prominence, muscle thickness, and patient-reported outcomes, but substantial heterogeneity limited interpretation of the magnitude of benefit. The authors could not establish a formulation-adjusted dose-response relationship or an optimal protocol. These pooled results do not establish superiority of Hengli, Botox, or another brand. (Masseter hypertrophy meta-analysis — JPRAS 🔗)
Earlier systematic work and a 2024 randomized study also illustrate why muscle thickness, electrical activity, chewing performance, and subjective appearance are separate outcomes. Differences in products, participants, outcome measures, and follow-up prevent a universal treatment protocol. (Masticatory-muscle hypertrophy systematic review — JCMS 🔗; Masseter hypertrophy randomized trial — Scientific Reports 🔗)
The evidence also depends on the question being asked. A study measuring muscle thickness or facial width does not answer whether treatment improves bruxism, temporomandibular joint disease, headache, or nonspecific jaw tension. Conversely, a pain study does not necessarily establish a predictable contouring result.
| Evidence question | Useful outcome | Common interpretation error |
|---|---|---|
| Does muscle volume change? | Ultrasound, imaging, or standardized width measurement over time. | Treating a change in size as proof of pain relief or functional benefit. |
| Does chewing function change? | Bite force, masticatory performance, fatigue, or patient-reported chewing difficulty. | Assuming desired weakening has no functional tradeoff. |
| Does facial appearance change? | Standardized photographs or dimensional measurements. | Treating subjective satisfaction as a product-to-product efficacy comparison. |
| Are repeated sessions well characterized? | Longer follow-up of muscle, function, soft tissue, and mandibular bone. | Extrapolating short studies to indefinite repeated use. |
Safety and Long-Term Uncertainty
Section titled “Safety and Long-Term Uncertainty”The masseter contributes to chewing and lower-face movement. Functional effects deserve separate assessment from changes in appearance: a 2024 randomized study evaluated muscle thickness, electrical activity, and chewing performance separately. Its findings cannot establish the safety of every product or repeated-treatment pattern. (Masseter hypertrophy randomized trial — Scientific Reports 🔗) Product-specific prescribing information also governs warnings about weakness and spread of toxin effect. (BOTOX prescribing information — DailyMed 🔗)
Mandibular bone effects remain an area of uncertainty. A 2024 systematic review found no clear pattern linking masticatory-muscle injections to bone resorption across the included studies. (Mandibular bone systematic review — Clinical Oral Investigations 🔗)
A 2026 placebo-controlled study of 187 healthy adults with masseter prominence found no detectable differences in predefined CT measures of mandibular morphology after one or two onabotulinumtoxinA treatments over 12 months. The study was funded by Allergan Aesthetics and included company authors. It does not settle effects beyond a year or with other products and exposure patterns. (Mandibular morphology study — Aesthetic Surgery Journal 🔗)
Product-specific units remain essential. Results obtained with one formulation and unit system cannot be converted into a recommendation for Botox, Dysport, Xeomin, Jeuveau / Nabota, or another product.
Related Pages
Section titled “Related Pages”- Glabellar lines
- Botulinum toxin type A
- Unit interpretation
- Injection anatomy overview
- Dose calculation overview
- Safety and adverse-effect framing

